Literature DB >> 11943472

The role of Rho GTPases in disease development.

Benjamin Boettner1, Linda Van Aelst.   

Abstract

The functionality and efficacy of Rho GTPase signaling is pivotal for a plethora of biological processes. Due to the integral nature of these molecules, the dysregulation of their activities can result in diverse aberrant phenotypes. Dysregulation can, as will be described below, be based on an altered signaling strength on the level of a specific regulator or that of the respective GTPase itself. Alternatively, effector pathways emanating from a specific Rho GTPase may be under- or overactivated. In this review, we address the role of the Rho-type GTPases as a subfamily of the Ras-superfamily of small GTP-binding proteins in the development of various disease phenotypes. The steadily growing list of genetic alterations that specifically impinge on proper Rho GTPase function corresponds to pathological categories such as cancer progression, mental disabilities and a group of quite diverse and unrelated disorders. We will provide an overview of disease-rendering mutations in genes that have been positively correlated with Rho GTPase signaling and will discuss the cellular and molecular mechanisms that may be affected by them.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11943472     DOI: 10.1016/s0378-1119(02)00426-2

Source DB:  PubMed          Journal:  Gene        ISSN: 0378-1119            Impact factor:   3.688


  68 in total

1.  High-throughput flow cytometry bead-based multiplex assay for identification of Rho GTPase inhibitors.

Authors:  Zurab Surviladze; Susan M Young; Larry A Sklar
Journal:  Methods Mol Biol       Date:  2012

2.  Involvement of Rho family GTPases in p19Arf- and p53-mediated proliferation of primary mouse embryonic fibroblasts.

Authors:  Fukun Guo; Yi Zheng
Journal:  Mol Cell Biol       Date:  2004-02       Impact factor: 4.272

Review 3.  Protein farnesylation and disease.

Authors:  Giuseppe Novelli; Maria Rosaria D'Apice
Journal:  J Inherit Metab Dis       Date:  2012-02-04       Impact factor: 4.982

4.  Rational design of small molecule inhibitors targeting RhoA subfamily Rho GTPases.

Authors:  Xun Shang; Fillipo Marchioni; Nisha Sipes; Chris R Evelyn; Moran Jerabek-Willemsen; Stefan Duhr; William Seibel; Matthew Wortman; Yi Zheng
Journal:  Chem Biol       Date:  2012-06-22

5.  Effects of the tumor inhibitory triterpenoid avicin G on cell integrity, cytokinesis, and protein ubiquitination in fission yeast.

Authors:  Jordan U Gutterman; Hong T Lai; Peirong Yang; Valsala Haridas; Amos Gaikwad; Stevan Marcus
Journal:  Proc Natl Acad Sci U S A       Date:  2005-08-23       Impact factor: 11.205

Review 6.  GTP-binding proteins of the Rho/Rac family: regulation, effectors and functions in vivo.

Authors:  Xosé R Bustelo; Vincent Sauzeau; Inmaculada M Berenjeno
Journal:  Bioessays       Date:  2007-04       Impact factor: 4.345

7.  RhoGTPases and p53 are involved in the morphological appearance and interferon-alpha response of hairy cells.

Authors:  Benjamin Chaigne-Delalande; Lynda Deuve; Edith Reuzeau; Caroline Basoni; David Lafarge; Christine Varon; Florence Tatin; Guerric Anies; Richard Garand; Ijsbrand Kramer; Elisabeth Génot
Journal:  Am J Pathol       Date:  2006-02       Impact factor: 4.307

8.  CNF1-induced ubiquitylation and proteasome destruction of activated RhoA is impaired in Smurf1-/- cells.

Authors:  Laurent Boyer; Laurent Turchi; Benoit Desnues; Anne Doye; Gilles Ponzio; Jean-Louis Mege; Motozo Yamashita; Ying E Zhang; Jacques Bertoglio; Gilles Flatau; Patrice Boquet; Emmanuel Lemichez
Journal:  Mol Biol Cell       Date:  2006-03-15       Impact factor: 4.138

9.  The DH and PH domains of Trio coordinately engage Rho GTPases for their efficient activation.

Authors:  Mariya K Chhatriwala; Laurie Betts; David K Worthylake; John Sondek
Journal:  J Mol Biol       Date:  2007-02-22       Impact factor: 5.469

Review 10.  Rho GTPases: functions and association with cancer.

Authors:  Saskia I J Ellenbroek; John G Collard
Journal:  Clin Exp Metastasis       Date:  2007-11-14       Impact factor: 5.150

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.